跳至主要内容
临床试验/NL-OMON53010
NL-OMON53010招募中不适用

Improving the clinical usefulness of skin biopsy in small fiber neuropathy: examining the intraepidermal nerve fiber density dynamic longitudinally and the importance of adding the proximal/distal ratio - Improving the clinical usefulness of skin biopsy in small fiber neuropathy

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Group 1 (n=40) Idiopathic SFN, with normal IENFD:
  • a) Male and female subjects of 18 years or older.
  • b) >=2 positive answers on the SFN-SIQ, not otherwise explained.
  • c) Normal IENFD and abnormal TTT, according to the international normative
  • values,3,23 during the regular visit in our clinical center at least one year
  • d) Written informed consent.Group 2 (n = 40) Sodium channelopathy-related SFN,
  • with normal IENFD:
  • a) Male and female subjects of 18 years or older.
  • b) >=2 positive answers on the SFN-SIQ, not otherwise explained.
  • c) Normal IENFD and abnormal TTT, according to the international normative
  • values,3,23 during the regular visit in our clinical center at least one year
  • d) Possibly pathogenic, probably pathogenic or pathogenic NaV1.7, Nav1.8 and/or
  • NaV1.9 variant
  • a) Written informed consent.Group 3 (n=140) Healthy subjects (only
  • proximal/distal IENFD ratio study)
  • a) Male and female subjects of 18 years or older.
  • b) Written informed consent.Group 4 (n = 20) Idiopathic SFN, with abnormal
  • IENFD (only proximal/distal IENFD ratio study)
  • a) Male and female subjects of 18 years or older.
  • b) >=2 positive answers on the SFN-SIQ, not otherwise explained.
  • c) Abnormal IENFD, according to the international normative values, during the
  • regular visit in our clinical center at least one year ago.
  • d) Written informed consent.When it appears that the proximal/distal ratio is
  • abnormal in patients with an abnormal TTT, but normal IENFD, the study will be
  • extended with an extra group of patients:Group 5 (n=40) Idiopathic clinical
  • SFN, with both normal IENFD and TTT
  • a) Male and female subjects of 18 years or older.
  • b) >=5 positive answers on the SFN-SIQ, not otherwise explained.
  • c) Patients with a normal IENFD and normal TTT, according to the international
  • normative values, during the regular visit in our clinical center at least one

排除标准

  • All patient groups:
  • a) Underlying cause of SFN (diabetes, hypothyroidism, renal failure, vitamin
  • B12 deficiency, monoclonal gammopathy, alcohol abuse (more than 5 IU/day),
  • malignancies, drugs that cause neuropathy (e.g. chemotherapy, amiodarone,
  • propafenone)).
  • b) Large nerve fiber involvement (i.e. weakness, loss of vibration sense,
  • hypo-/areflexia, abnormal nerve conduction studies).Groups 1, 4 and 5
  • a) Possibly pathogenic, probably pathogenic or pathogenic NaV1.7, Nav1.8 and/or
  • NaV1.9 variant.Healthy subjects
  • a) >1 positive answer on the SFN-SIQ.
  • b) A history of peripheral neuropathy.
  • c) Signs of peripheral neuropathy in neurological examination.nt claCC

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验

Improving the clinical usefulness of skin biopsy in... | 临床试验